<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10576660</article-id><article-id pub-id-type="pmc">2362937</article-id><article-id pub-id-type="pii">6690802</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690802</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brada</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Judson</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beale</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reidenberg</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Statkevich</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dugan</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Batra</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cutler</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>The Royal Marsden NHS Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK</aff><aff id="aff2"><label>2</label>637 South Chestnut Street, Westfield, NJ 07090, USA</aff><aff id="aff3"><label>3</label>Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA</aff><pub-date pub-type="ppub"><month>11</month><year>1999</year></pub-date><volume>81</volume><issue>6</issue><fpage>1022</fpage><lpage>1030</lpage><history><date date-type="received"><day>04</day><month>01</month><year>1999</year></date><date date-type="rev-recd"><day>30</day><month>04</month><year>1999</year></date><date date-type="accepted"><day>07</day><month>06</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Temozolomide, an oral cytotoxic agent with approximately 100&#x00025; bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers. Thirty patients with minimal prior chemotherapy were enrolled in this phase I trial to characterize the drug's safety, pharmacokinetics and anti-tumour activity, as well as to assess how food affects oral bioavailability. To determine dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD), temozolomide 100&#x02013;250 mg m<sup>&#x02212;2</sup> was administered once daily for 5 days every 28 days. The DLT was thrombocytopenia, and the MTD was 200 mg m<sup>&#x02212;2</sup> day<sup>&#x02212;1</sup>. Subsequently, patients received the MTD to study how food affects the oral bioavailability of temozolomide. When given orally once daily for 5 days, temozolomide was well tolerated and produced a non-cumulative, transient myelosuppression. The most common non-haematological toxicities were mild to moderate nausea and vomiting. Clinical activity was observed against several advanced cancers, including malignant glioma and metastatic melanoma. Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean <italic>T</italic><sub>max</sub> ~1 h) and eliminated (mean t<sub>1/2</sub> = 1.8 h). Food produced a slight reduction (9&#x00025;) in absorption of temozolomide. Temozolomide 200 mg m<sup>&#x02212;2</sup> day<sup>&#x02212;1</sup> for 5 days, every 28 days, is recommended for phase II studies. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>oral</kwd><kwd>cytotoxic</kwd><kwd>chemotherapy</kwd><kwd>pharmacokinetics</kwd><kwd>dose escalation</kwd></kwd-group></article-meta></front></article>


